Maltodextrin is two ingredients sharing one name. The digestible form acts as fast sugar — strong, consistent evidence — useful mainly for fueling long exercise and, compared with fasting, before surgery; a cost otherwise. The rearranged, indigestible form modestly improves blood sugar control on pooled trial evidence; inflammation, blood fat and sleep findings rest on one research group. (Full Review)
| Marker | Target | Why |
|---|---|---|
| Fasting glucose | 75–86 mg/dL | Cumulative cost of repeated glucose loads |
| Fasting insulin | 2–5 μIU/mL | Rises before glucose does; earliest signal of a problem |
| Glycated hemoglobin | 4.8–5.3% | Three-month average glucose; the outcome the resistant form moved |
| Insulin resistance index | Below 1.0 | Single number combining fasting glucose and insulin |
| Triglycerides | Below 80 mg/dL | The lipid fraction most responsive to carbohydrate load and to the resistant form |
| Triglyceride-to-high-density-lipoprotein ratio | Below 1.5 | Practical proxy for insulin resistance and small dense lipoprotein particles |
| High-sensitivity C-reactive protein | Below 0.5 mg/L | Tracks the inflammation the resistant form reduced in trials |
| Post-meal glucose peak | Below 140 mg/dL, back to baseline within 2 hours | Direct readout of how a given dose behaves in one individual |
| Stool form and frequency | 1–2 daily, Bristol Stool Scale type 3–4 | The limiting factor for resistant-form dosing |
Cadence: Baseline metabolic panel before either form is started. Bowel symptoms weekly during resistant-form titration. Panel and inflammatory marker at 12 weeks, then every 6–12 months. Continuous glucose monitoring repeated at 12 weeks for regular digestible-form use.